Dyspepsia: Detailed Overview

1. Definition

2. Classification: Organic vs. Functional Dyspepsia

• Peptic ulcer disease (found in only 5-10% of dyspeptic patients; risk factors are NSAID use, H. pylori infection, and increasing age)
• Gastroesophageal reflux disease (GERD), including nonerosive reflux disease
• Gastric or esophageal malignancy (uncommon but important to exclude)
• Biliary and pancreatic disorders (cholelithiasis, chronic pancreatitis)
• Drug-induced dyspepsia (NSAIDs, antibiotics, iron, potassium)
• Other systemic disease (diabetic gastroparesis, thyroid disease, celiac disease)

• Postprandial Distress Syndrome (PDS) - meal-related fullness and early satiety; ~60-65% of FD patients; more associated with delayed gastric emptying and antral hypomotility; responds better to prokinetics.
• Epigastric Pain Syndrome (EPS) - meal-unrelated epigastric pain or burning; ~15% of FD patients; more associated with visceral hypersensitivity and impaired gastric accommodation.

3. Pathophysiology of Functional Dyspepsia

• Delayed gastric emptying (present in ~25-30% of FD patients, correlates with PDS symptoms)
• Impaired gastric accommodation to a meal (fundic relaxation failure), correlating with early satiety
• Visceral hypersensitivity to gastric distension or acid
• Duodenal eosinophilia and increased mucosal permeability (a newer mechanistic model)
• Low-grade duodenal inflammation, possibly triggered by prior enteric infection
• H. pylori infection - implicated in a subset of patients
• Psychosocial factors: anxiety, depression, somatization

4. Diagnostic Approach and Alarm Features

5. Pharmacotherapy of Dyspepsia

• Proton pump inhibitors (PPIs) are first-line empirical therapy, particularly effective for EPS-predominant symptoms and reflux-related dyspepsia. A 4-8 week trial is standard.
• H2-receptor antagonists (H2RAs) are an alternative, generally less effective than PPIs but useful for milder symptoms or as step-down therapy.
• Antacids provide symptomatic relief but are not generally effective for functional dyspepsia as sole therapy (Goodman & Gilman's Pharmacological Basis of Therapeutics).

• Indicated in all patients testing positive. Standard regimens combine a PPI with two antibiotics (commonly amoxicillin plus clarithromycin or metronidazole) for 10-14 days; eradication rates approach 90% with optimized regimens (Bailey and Love's Short Practice of Surgery, 28th ed.).
• In functional dyspepsia specifically, eradication produces a modest but statistically significant benefit - a pooled meta-analysis (25 controlled trials) found roughly a 9% risk reduction in symptoms compared to placebo (Harrison's Principles of Internal Medicine 22E).

• Metoclopramide (dopamine D2 antagonist; limited by central side effects - extrapyramidal symptoms, tardive dyskinesia with prolonged use)
• Domperidone (peripheral D2 antagonist, fewer CNS effects but QT prolongation risk)
• Itopride, prucalopride (5-HT4 agonist, more evidence in gastroparesis than FD)

• Buspirone (5-HT1A agonist, 10 mg three times daily) improves gastric accommodation and has demonstrated efficacy, particularly in PDS.
• Tandospirone is used similarly in some regions.

• Low-dose tricyclic antidepressants (amitriptyline, nortriptyline, imipramine) - modest evidence base, useful in EPS
• Mirtazapine (15 mg at bedtime) - improves symptoms and also promotes weight gain/appetite, useful in patients with early satiety and weight loss; superior to placebo in controlled trials
• A meta-analysis of 13 trials found modest overall benefit of antidepressants in FD, though individual trial quality varies (Harrison's Principles of Internal Medicine 22E, "Centrally Acting Neuromodulators").

• Cognitive behavioral therapy, hypnotherapy, and mindfulness-based approaches are recommended adjuncts, especially when psychosocial comorbidity or refractory symptoms are present.

6. Recent Evidence (Supplementary PubMed Check)

• Psychotherapeutic approaches for FD - a 2024 systematic review/meta-analysis found CBT, hypnotherapy, and mindfulness produce meaningful symptom and quality-of-life improvement, reinforcing the textbook recommendation for psychological therapy as an adjunct (PMID: 39210762).
• Exercise therapy for FD - a 2025 systematic review/meta-analysis suggests structured exercise may improve FD symptoms and quality of life, an intervention not emphasized in older textbook chapters (PMID: 40619318).
• Acupuncture for FD - a 2024 Bayesian network meta-analysis found some benefit, though this remains a complementary/lower-certainty intervention (PMID: 38761869).

Summary Treatment Algorithm

1. Exclude alarm features -> endoscopy if present or age >45-60
2. Test for H. pylori; eradicate if positive
3. Empirical PPI trial (4-8 weeks) if H. pylori-negative or symptoms persist after eradication
4. If refractory, classify by Rome IV subtype:
   • PDS -> prokinetic (metoclopramide/domperidone) or buspirone
   • EPS -> continue/optimize PPI, add TCA or mirtazapine
5. Add psychological therapy (CBT) for refractory or psychosocially-complicated cases

Dyspepsia: Risk Factors and Management

Risk Factors

• Age above 40-55/60 years (increased risk of malignancy)
• NSAID or aspirin use (peptic ulcer risk)
• Helicobacter pylori infection (major risk factor for peptic ulcer disease and gastric cancer)
• Presence of "alarm features": unintentional weight loss, dysphagia/odynophagia, persistent vomiting, GI bleeding or iron-deficiency anemia, palpable abdominal mass, family history of upper GI cancer, personal history of peptic ulcer or prior gastric surgery

• Female sex
• Smoking
• NSAID use
• Acute gastroenteritis / postinfectious state - well-documented trigger; postinfectious gastroenteritis increases risk of subsequently developing FD, similar to the mechanism seen in postinfectious IBS
• Psychological disorders, particularly anxiety and depression - both as a risk factor and as a frequent comorbidity (FD overlaps with IBS, fibromyalgia, and chronic fatigue syndrome)
• H. pylori infection - a minor contributing factor in FD (unlike its strong causal role in peptic ulcer disease)
• Early-life factors and genetic predisposition - per Drossman's biopsychosocial model, early-life environmental influences plus genetic susceptibility interact with later psychosocial stress to produce disordered gut-brain interaction
• Altered hypothalamic-pituitary-adrenal axis activity and duodenal eosinophilia/mast cell infiltration are emerging biological risk correlates

Management

• Age <45-60 without alarm features -> manage empirically (no immediate endoscopy needed)
• Age >45-60 OR any alarm feature present -> upper endoscopy (EGD) first to exclude peptic ulcer, malignancy, or esophagitis

• Noninvasive testing (urea breath test or stool antigen) in average-risk patients
• If positive -> eradication therapy: PPI plus two antibiotics (commonly amoxicillin + clarithromycin, or amoxicillin + metronidazole) for 10-14 days; eradication rates ~90% with optimized regimens
• If negative, or symptoms persist after eradication -> empirical PPI trial

• PPI for 4-8 weeks is first-line empirical therapy, especially effective for reflux-related and epigastric pain syndrome (EPS) presentations
• H2-receptor antagonists as an alternative or step-down option

• Psychological therapies: CBT, hypnotherapy, mindfulness - recommended for refractory symptoms or significant psychiatric comorbidity. A 2024 systematic review/meta-analysis (PMID: 39210762) confirmed meaningful benefit of psychotherapeutic interventions in FD.
• Exercise therapy: emerging evidence (2025 systematic review/meta-analysis, PMID: 40619318) suggests structured exercise improves FD symptoms and quality of life - a useful low-risk adjunct not traditionally emphasized in older texts.
• Dietary modification: smaller, more frequent low-fat meals; avoidance of trigger foods, alcohol, and smoking cessation
• Complementary options: acupuncture has shown some benefit in network meta-analysis (PMID: 38761869) but remains lower-certainty evidence

• Discontinue or switch NSAIDs where possible
• Reassurance and patient education are important given the chronic, relapsing nature of FD
• Antacids provide symptomatic relief only and are not effective as monotherapy for functional dyspepsia
• Reassess and consider additional investigation (gastric emptying studies, biliary imaging) if first-line strategies fail